Editor’s note: Discover the most recent COVID-19 news and assistance in Medscape’s Coronavirus Resource Center
Full-dose anticoagulation transcended to low, prophylactic dosages in minimizing the requirement for crucial organ support such as ventilation in moderately ill clients hospitalized for COVID-19, according to a report launched today by the National Institutes of Health (NIH).
” We have treatments that are enhancing outcomes however not as lots of that minimize death, so we’re confident when the complete dataset comes in that will be verified,” she stated.
The observation of increased rates of embolism and swelling among COVID-19 clients, which can lead to issues such as lung failure, heart attack, and stroke, has generated different anticoagulant treatment protocols and a need for randomized information on consistently administering increased dosages of anticoagulation to hospitalized patients.
Today’s top-line findings come from 3 linked clinical trials– REMAP-CAP, ACTIV- 4, and ATTACC— taking a look at the safety and efficacy of full-dose anticoagulation to treat moderately ill or seriously ill adults hospitalized with COVID compared to a lower dosage normally used